Keywords
How to Cite
Abstract
Joint damage in patients with diabetes mellitus (DM) is a common complication and is associated with the induction of metabolic inflammation against the background of increased catabolic processes in various joint structures. The aim of our study was a study of the levels of proinflammatory cytokines in the serum of patients with diabetes-associated osteoarthritis. Materials and methods. We examined 118 patients, who were divided into groups according to the type of diabetes, the presence and severity of diabetic arthropathy. The content of IL-1α, IL-6, S IL-6-R receptors, TNF-α, osteoprotegerin (soluble TNF-α receptor) in blood serum was determined by enzyme-linked immunosorbent assay. Results Among the examined patients, diabetic arthropathy was diagnosed in more than 70% of patients with diabetes of both types. In patients with diabetic arthropathy, levels of TNF-α (44.5% in type 1 diabetes, 42.9% in type 2 diabetes) and its soluble osteoprotegerin receptor (74.1% in type 1 diabetes) were significantly increased. Type 2 diabetes by 52.9%, as well as IL-6 (with type 1 diabetes by 52.1%, with type 2 diabetes by 64.4%) There is a direct correlation between the severity of joint damage and the level of TNF-α , osteoprotegerin and IL-6. For IL-1, S IL-6-R receptors such changes were not detected.The chances of detecting arthropathy with increasing levels of TNF-a in type 1 diabetes increase by 1.7 (OR = 1, 70 ; DI 1,19-2,44) times, at D 2 type - 1.8 times (OR = 1.78; DI 1.21-1.2.61), with an increase in IL-6 in type 1 diabetes increase by 1.5 (OR = 1.47; DI 1.08 -1.98) times, with type 2 diabetes - 1.3 times (OR = 1.34; DI 1.03-1.74), with elevated levels of osteoprotegerin diabetic arthropathy is 2.3 times more common in patients with type 1 diabetes (OR = 2.33; DI 1.42-3.82) and 1.6 times in patients with type 2 diabetes (SHR = 1.55; DI 1.14-2.10). Conclusions. Thus, TNF-α, osteoprotegerin, and IL-6 may serve as markers of the presence and progression of joint damage in patients with diabetes.
References
Dong Q., Degree B., Liu H., Yang D., Zhang Y. (2017). Diabetes mellitus and arthritis: is it a risk factor or comorbidity? A systematic review and meta-analysis Medicine (Baltimore), 96 (18), e6627. doi: 1097/MD.0000000000006627
Shikhman A.R., Brinson D.C., Valbracht J., Lotz M.K. (2001). Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J. Immunol, 167, 7001–08. doi: 10.4049/jimmunol.167.12.7001
Williams M. F., London D. A., Husni E. M., Navaneethan S., Kashyap S. R. (2016). Type 2 diabetes and osteoarthritis: a systematic review and meta-analysis. J Diabetes Complications, 30 (5), 944–50. doi: 10.1016/j.jdiacomp.2016.02.016.
Schett G., Kleyer A., Perricone C., Sahinbegovic E., Iagnocco A., Zwerina J. (2013). Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study Diabetes Care, 36(2), 403–09. doi: 10.2337/dc12-0924
Louati K., Vidal C., Berenbaum F., Sellam J. (2015). Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis,” R.M.D. Open, 1(1): e000077. doi: 10.1136/rmdopen-2015-000077
Shirinskij I.V., Kalinovskaya N.Yu., Shirinskij V.S (2015) Kliniko-immunologicheskaya harakteristika diabet-associirovannogo osteoartrita [Clinical and immunological characteristics of diabetes-associated osteoarthritis]. Meditsinskaya Immunologiya, 17, 87-92. doi: 10.15789/1563-0625-2015-1-87-92
Berenbaum F. (2011). Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. Ann. Rheum. Dis., 70, 1354–56. doi:10.1136/ard.2010.146399 19.
Rosa S.C., Rufino A.T, Judas F., Tenreiro C., Lopes M.C., Mendes A.F. (2011). Expression and function of the insulin receptor in normal and osteoarthritic human chondrocytes: modulation of anabolic gene expression, glucose transport and GLUT-1 content by insulin. Osteoarthritis and Cartilage, 19, 719–27. doi: 10.1016/j.joca.2011.02.004
Shikhman A.R, Brinson D.C, Valbracht J, Lotz M.K. (2001). Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol, 67(12), 7001-08. doi: 10.4049/jimmunol.167.12.7001
Mabey T., Honsawek S. (2015). Cytokines as biochemical markers for knee osteoarthritis World J. Orthop, 6(1), 95–105. doi: 10.5312/wjo.v6.i1.95.
Kapoor M., Martel-Pelletier J., Lajeunesse D., Pelletier J.P., Fahmi H. (2011). Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol, 7(1), 33-42. doi: 10.1038/nrrheum.2010.196.
Goldring M., Otero B.M. (2011) .Osteoarthritis and cartilage: the role of cytokines Curr Opin Rheumatol, 23(5), 471-8. doi: 10.1097/BOR.0b013e328349c2b1
Kwan Tat S., Amiable N., Pelletier J.P., Boileau C., Lajeunesse D., Duval N., Martel-Pelletier J. (2009). Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. Rheumatology (Oxford), 48(12), 1482-1490. doi: 10.1093/rheumatology/kep300.
Tat S.K., Pelletier J.P., Velasco C.R., Padrines M., Martel-Pelletier J. (2009). New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target? Keio J Med, 58(1), 29-40.
Shimizu S., Asou Y., Itoh S., Chung U.I, Kawaguchi H., Shinomiya K., Muneta T. (2007). Prevention of cartilage destruction with intraarticular osteoclastogenesis inhibitory factor/osteoprotegerin in a murine model of osteoarthritis. Arthritis and Rheumatism, 56(10), 3358-65. doi: 10.1002/art.22941
Rajmuev K.V., Ishenko A.M., Malyshev M.E. (2018). Provospalitelnye i protivovospalitelnye citokiny v patogeneze osteoartrita [Pro-inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis] Herald of North-Western State Medical University named after I.I. Mechnikov, 10(3), 19-27. doi: 10.17816/
Zonova E. V., Lykov A. P , Trifonova E. P. Sazonova O. V. (2016). Characterization of osteoarthritis in patients with diabetes mellitus type 2. Integ.r Mol. Med, 3(3), 649-653. doi: 10.15761/IMM.1000217
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.